Description
Essential B12 contains nature’s form of B12 called hydroxocobalamin. Hydroxocobalamin converts to methylcobalamin, (the form that is ultimately used by most cells in the body) – seamlessly and locally as needed. Local requirements safely determine the speed of methylcobalamin conversion. Hydroxocobalamin is also easily converted to adenosylcobalamin, a form of B12 preferred by mitochondria while methyl B12 is not cross converted. Methylcobalamin is uniquely able to convert metallic mercury to methylmercury, a more toxic form. Hydroxocobalamin, nature’s preferred B12 form, does not have this adverse effect.
Ingredients
A 12-week study, in 2010, conducted by the M.I.N.D Institute (1) on the effect of methylcobalamin in 30 autistic children showed that methylcobalamin is statistically ineffective in treating behavioral symptoms of autism. A subset of nine subjects, however, showed positive behavioral changes confirming that methylation may be important in a subgroup of those with autistic spectrum disorders (ASD).
Hydroxocobalamin has a half-life of days and is converted locally to methylcobalamin as needed. Methylcobalamin has a very short half-life, measurable in minutes to hours.
Peer reviewed literature confirms that hydroxocobalamin has a superior functionality compared to other forms like cyanocobalamin and methylcobalamin.
Peer reviewed literature confirms that hydroxocobalamin has a superior functionality compared to other forms like cyanocobalamin and methylcobalamin.
References
† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
- 1. Bertoglio K, James S, Daprey L, Norman B, Hendren R. Pilot Study of the Effect of MethylB12 treatment on Behavioral and Biomarker Measures in Children with Autism, JACM, Accepted March 2010.
- Paul C, Brady DM. Comparative Bioavailability and Utilization of Particular Forms of B12 Supplements With Potential to Mitigate B12-related Genetic Polymorphisms. Integr Med (Encinitas). 2017;16(1):42-49.
- Elian KM, Hoffer LJ. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism. 2002 Jul; 51(7):881-886
- Hoffer LJ, Elian KM. Parenteral vitamin B12 therapy of hyperhomocysteinemia in end-stage renal disease. Clin Invest Med. 2004 Feb;27(1):10-13.
- den Heijer M, Brouwer IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendaal FR, Thomas CM, Haak HL, Wijermans PW, Gerrits WB. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol. 1998 Mar;18(3):356-361.
- Ogier de Baulny H, Gérard M, Saudubray JM, Zittoun J. Remethylation defects: Guidelines for clinical diagnosis and treatment. Eur J Pediatr. 1998 Apr;15 7 Suppl 2:S77-S83.
Warnings
Always be sure to speak with your healthcare provider before starting any new nutritional supplement when pregnant or nursing. For children, we recommend speaking with your child's pediatrician regarding proper dosing. Store away from children.
Reviews